Antibiotic Resistance in Dermatology: An Interview With James Q. Del Rosso, DO

Antimicrobial resistance is a growing concern that threatens the effective treatment of infectious diseases worldwide. Efforts to mitigate the indiscriminate use of antibiotics that contributes to the development of resistance are urgently needed.

The following clips were taken from an interview with James Q. Del Rosso, DO, in which he spoke about antibiotic resistance in dermatology. He particularly focused on how dosing outside of the mutant selection window may be an approach to lessen the formation of multidrug-resistant mutants.

Video 1 of 3: Antibiotic Resistance in Dermatology

In this video, James Q. Del Rosso, DO, explores concerns about the impact of antibiotic resistance in the dermatology community, discussing the risks of the continued increase in resistance, and why dermatologists need to change the way they use antibiotics.

Up Next

Video 1 of 3: Antibiotic Resistance in Dermatology
Video 2 of 3: Antibiotic-Resistant Mutations
Video 3 of 3: The Mutant Selection Window

This educational activity is sponsored by Foamix Pharmaceuticals Inc.


James Q. Del Rosso, DO

  • Research Director
  • JDR Dermatology Research/Thomas Dermatology
  • Las Vegas, Nevada
  • Adjunct Clinical Professor (Dermatology)
  • Touro University Nevada
  • Henderson, Nevada

Author Information

Board certified since 1988, James Q. Del Rosso, DO, is an internationally renowned speaker and educator with more than twenty years’ worth of dermatology research experience. James Q. Del Rosso, DO, has authored guidelines for the management of acne, rosacea, atopic dermatitis, psoriasis, and skin cancer. He is the recipient of the American Academy of Dermatology’s Lifetime Achievement Award for his contributions to the field of dermatology.

Author Disclosures

James Q. Del Rosso, DO, is a consultant for Aclaris, Almirall, Athenex, BioPharmX, Cutanea, Dermira, Ferndale Laboratories, Foamix Pharmaceuticals Inc., Galderma, LEO Pharma, Menlo Therapeutics, Novan, Ortho, Pfizer, Promius, Sanofi Genzyme/Regeneron, SkinFix, and Sun Pharma; he has received research support from Aclaris, Almirall, Athenex, BioPharmX, Botanix, Celgene, Cutanea, Dermira, Foamix Pharmaceuticals Inc., Galderma, Genentech, LEO Pharma, Menlo Therapeutics, Novan, Ortho, Promius, Regeneron, Sun Pharma, and Thync; he participates in speakers bureaus for honoraria from Aclaris, Almirall, Celgene, Galderma, Genentech, LEO Pharma, Ortho, Pfizer, Promius, Sanofi/ Regeneron, and Sun Pharma.

References

  1. Barbieri JS, et al. J Am Acad Dermatol. 2017;77(3):456-463.
  2. Coates P, et al. Br J Dermatol. 2002;146(5):840-848.
  3. Day T, Read AF. PLoS Comput Biol. 2016;28(12,1):e1004689.
  4. Del Rosso JQ, et al. J Clin Aesthet Dermatol. 2016;9(4):18-24.
  5. Del Rosso JQ, Zeichner JA. Dermatol Clin. 2016;34(2):167-173.
  6. Drlica K. J Antimicrob Chemother. 2003;52(1):11-17.
  7. Eady EA, et al. Br J Dermatol. 1989;121(1):51-57.
  8. Fong W, Drlica K, eds. Antimicrobial Resistance and Implications for the Twenty-First Century. New York: Springer; 2008.
  9. Kouyos RD, et al. Proc Bio Sci. 2014;281(1794):20140566.
  10. Martinez JL, Baquero F. Ups J Med Sci. 2014;119(2):68-77.
  11. Mills O Jr, et al. Acta Derm Venereol. 2002;82(4):260-265.
  12. Nast A, et al. J Eur Acad Dermatol Venereol. 2016;30(8):1261-1268.
  13. Ross JI, et al. Br J Dermatol. 2003;148(3):467-478.
  14. Skidmore R, et al. Arch Dermatol. 2003;139(4):459-464.
  15. World Health Organization. Antimicrobial resistance: Global report on surveillance 2014. Geneva, Switzerland: WHO; 2014.
  16. Wright GD. BMC Biology. 2010;8:123.
  17. Zaenglein AL, et al. J Am Acad Dermatol. 2016;74(5):945-973.e33.

MA-UNB-US-190005